BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17981213)

  • 1. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia.
    Lahiri O; Harris S; Packham G; Howell M
    Cancer Genet Cytogenet; 2007 Nov; 179(1):36-44. PubMed ID: 17981213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.
    Willander K; Ungerbäck J; Karlsson K; Fredrikson M; Söderkvist P; Linderholm M
    Eur J Haematol; 2010 Sep; 85(3):251-6. PubMed ID: 20491880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.
    Kaderi MA; Mansouri M; Zainuddin N; Cahill N; Gunnarsson R; Jansson M; Kimby E; Aleskog A; Lundin J; Glimelius B; Melbye M; Juliusson G; Jurlander J; Rosenquist R
    Leuk Res; 2010 Mar; 34(3):335-9. PubMed ID: 19573916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression.
    Moshynska O; Moshynskyy I; Misra V; Saxena A
    Oncogene; 2005 Mar; 24(12):2042-9. PubMed ID: 15688029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
    Asslaber D; Piñón JD; Seyfried I; Desch P; Stöcher M; Tinhofer I; Egle A; Merkel O; Greil R
    Blood; 2010 May; 115(21):4191-7. PubMed ID: 20089965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long intergenic non-coding RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia.
    Abo Elwafa R; Abd Elrahman A; Ghallab O
    Clin Transl Oncol; 2021 Jan; 23(1):92-99. PubMed ID: 32468342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive single nucleotide polymorphism study supports the role of MDM2 in p53-competent chronic lymphocytic leukemia.
    Lucas DM; Byrd JC
    J Clin Oncol; 2008 May; 26(14):2244-5. PubMed ID: 18467712
    [No Abstract]   [Full Text] [Related]  

  • 10. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia.
    Isin M; Yenerel M; Aktan M; Buyru N; Dalay N
    DNA Cell Biol; 2012 May; 31(5):777-82. PubMed ID: 22047081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated.
    Starczynski J; Pepper C; Pratt G; Hooper L; Thomas A; Milligan D; Bentley P; Fegan C
    J Clin Oncol; 2005 Mar; 23(7):1514-21. PubMed ID: 15735127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
    Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
    Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia.
    Skogsberg S; Tobin G; Kröber A; Kienle D; Thunberg U; Aleskog A; Karlsson K; Laurell A; Merup M; Vilpo J; Sundström C; Roos G; Jernberg-Wiklund H; Döhner H; Nilsson K; Stilgenbauer S; Rosenquist R
    Leukemia; 2006 Jan; 20(1):77-81. PubMed ID: 16307023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.
    McGraw KL; Cluzeau T; Sallman DA; Basiorka AA; Irvine BA; Zhang L; Epling-Burnette PK; Rollison DE; Mallo M; Sokol L; Solé F; Maciejewski J; List AF
    Oncotarget; 2015 Oct; 6(33):34437-45. PubMed ID: 26416416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
    Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
    Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
    J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
    Saddler C; Ouillette P; Kujawski L; Shangary S; Talpaz M; Kaminski M; Erba H; Shedden K; Wang S; Malek SN
    Blood; 2008 Feb; 111(3):1584-93. PubMed ID: 17971485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
    Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
    J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.